Development and application of HPV31-specific monoclonal antibodies

Figures & data

Figure 1. The reactivity of 19B4 and 19C2 towards HPV31 L1-VLPs.

Figure 2. Specificities of 19B4 (A) and 19C2 (B) to native or denatured HPV L1-VLPs.

Table 1. Characteristics of the HPV31 L1-VLP mAbs.

mAb	Isotype^a	Epitope recognized	Inhibitory concentration of mAbs against HPV-PsV infection
			IC50	IC90
19B4	IgG1	C^b	15.183	>100
19C2	IgG1	C	1.320	62.201

^a Antibody isotype, classified by indirect ELISA.

^b Conformational epitope, confirmed by indirect ELISA.

Table 2. Competition between the two mAbs, or between mAbs and rabbit pAbs in vitro.

	Inhibition rate
mAb	19C2	Rabbit pAbs (0.1 µg/mL)
19B4	22.71%	89.20%
19C2	90.10%	92.30%

pAbs, polyclonal antibody.

Figure 3. Alignments of amino acid sequences of the (A) light- and (B) heavy-chain regions of monoclonal antibodies (mAbs) 19B4 and 19C2. Complementarity-determining regions (CDRs) are shaded gray.

Figure 4. Characterization of the HPV31 L1-VLP test kit developed in this study. (A) Linearity of HPV31 test kit; (B) specificity of HPV31 test kit.

Table 3. Recovery ratio of HPV31 antigen concentration.

	Antigen concentration (μg/mL)
	10	3.3333	1.1111	0.3704	0.1235
Group 1	87.7%	87.3%	106.3%	116.0%	100.5%
Group 2	96.4%	92.3%	101.6%	111.2%	99.8%
Group 3	85.9%	88.6%	106.8%	111.9%	102.9%
Mean	89.9%	89.5%	104.7%	112.8%	101.0%

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article.